Knight Therapeutics Inc. (Knight) is a specialty pharmaceutical company. The Company is focused on developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products. The Company's product pipeline consists of the product Impavido (miltefosine), an alkyllysophospholipid analogue drug with in vitro activity against the promastigote and amastigote stages of Leishmania species. Impavido is an oral agent indicated for the treatment of visceral and cutaneous leishmaniasis and was included in the World Health Organization (WHO) essential medicines list as an anti-leishmaniasis medicine.
Industry, Sector and Symbol:
- Sector: N/A
- Industry: N/A
- Sub-Industry: N/A
- Symbol: CVE:GUD
- CUSIP: N/A
- Web: N/A
- Market Cap: C$1.42 billion
- Outstanding Shares: 142,720,000
- 50 Day Moving Avg: C$10.34
- 200 Day Moving Avg: C$10.26
- 52 Week Range: C$7.88 - C$11.03
Sales & Book Value:
- Trailing P/E Ratio: 55.84
- P/E Growth: 2251.00
- Annual Revenue: C$6.62 million
- Price / Sales: 214.30
- Book Value: C$6.89 per share
- Price / Book: 1.44
- Average Volume: 142,816 shs.
- Short Ratio: 4.64
Frequently Asked Questions for Knight Therapeutics (CVE:GUD)
What is Knight Therapeutics' stock symbol?
Knight Therapeutics trades on the Canadian Venture Exchange (CVE) under the ticker symbol "GUD."
Who are some of Knight Therapeutics' key competitors?
Some companies that are related to Knight Therapeutics include Parex Resources (PXT), Raging River Exploration (RRX), Africa Oil Corp (AOI), Ithaca Energy (IAE), Sandstorm Gold Ltd (SSL), Painted Pony Petroleum Ltd (PPY), Tamarack-Valley-Energy-Ltd (TVE), Surge Energy (SGY), Integra Gold Corp (ICG), Tidewater Midstream & Infrastructure Ltd (TWM), Falcon Oil & Gas Ltd (FO), Leucrotta Exploration (LXE), Victoria Gold Corp (VIT), Blackbird Energy (BBI), TIO Networks Corp (TNC), CanElson Drilling (CDI), Belo Sun Mining Corp (BSX) and WesternZagros Resources (WZR).
How do I buy Knight Therapeutics stock?
Shares of Knight Therapeutics and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
How much does a share of Knight Therapeutics stock cost?
One share of Knight Therapeutics stock can currently be purchased for approximately C$9.94.
Consensus Ratings for Knight Therapeutics (CVE:GUD) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Knight Therapeutics (CVE:GUD)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Knight Therapeutics (CVE:GUD)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Knight Therapeutics (CVE:GUD)
Current Year EPS Consensus Estimate: $0.15 EPS
Dividend History for Knight Therapeutics (CVE:GUD)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Knight Therapeutics (CVE:GUD)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Knight Therapeutics (CVE:GUD)
Latest Headlines for Knight Therapeutics (CVE:GUD)
Knight Therapeutics (GUD) Chart for Wednesday, May, 24, 2017